The Pharmacokinetics of Oxycodone

References

• Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639–46
   PubMed Web of Science ®Google Scholar
• Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991; 35: 642–6
   PubMed Web of Science ®Google Scholar
• Benziger D P, Miotto J, Grandy R P, Thomas G B, Swanton R E, Fitzmartin R D. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. J Pain Symptom Manage 1997; 13: 75–82
   PubMed Web of Science ®Google Scholar
• Leow K P, Smith M T, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52: 487–95
   PubMed Web of Science ®Google Scholar
• Kaplan R, Parris W C, Citron M L, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 1998; 16: 3230–7
   PubMed Web of Science ®Google Scholar
• Reder R F, Oshlack B, Miotto J B, Benziger D D, Kaiko R F. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther 1996; 18: 95–105
   PubMed Web of Science ®Google Scholar
• Poyhia R, Seppala T, Olkkola K T, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33: 617–21
   PubMed Web of Science ®Google Scholar
• Mandema J W, Kaiko R F, Oshlack B, Reder R F, Stanski D R. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996; 42: 747–56
   PubMed Web of Science ®Google Scholar
• Product Information: OxyContin(R) controlled-release oxycodone. Purdue Pharma L.P., Stamford, CT 2003
   Google Scholar
• Benziger D, Kaiko R, Miotto J, Fitzmartin R, Reder R, Chasin M. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci 1996; 85: 407–10
   PubMed Web of Science ®Google Scholar
• Colucci R, Swanton R, Thomas G, Kaiko R. Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine. Am J Ther 2001; 8: 231–6
   Google Scholar
• Leow K, Wright A, Cramond T, Smith M. Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit 1993; 15: 440–7
   PubMed Web of Science ®Google Scholar
• Leow K, Smith M, Watt J, Williams B, Cramond T. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992; 14: 479–84
   PubMed Web of Science ®Google Scholar
• Plummer J L, Cmielewski P L, Reynolds G D, Gourlay G K, Cherry D A. Influence of polarity on dose-response relationships of intrathecal opioids in rats. Pain 1990; 40: 339–47
   PubMed Web of Science ®Google Scholar
• Gammaitoni A, Davis M. Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations. J Clin Pharmacol 2002; 42: 192–7
   PubMed Web of Science ®Google Scholar
• Chen Z R, Irvine R J, Somogyi A A, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165–71
   PubMed Web of Science ®Google Scholar
• Lalovic B, Phillips B, Risler L, Howald W, Shen D. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32: 447–54
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Olkkola K T, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64: 603–11
   PubMed Web of Science ®Google Scholar
• Beaver W T, Wallenstein S L, Rogers A, Houde R W. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther 1978; 207: 101–8
   PubMed Web of Science ®Google Scholar
• Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284–95
   PubMed Web of Science ®Google Scholar
• Otton S V, Wu D, Joffe R T, Cheung S W, Sellers E M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401–9
   PubMed Web of Science ®Google Scholar
• Kaiko R, Benziger D, Fitzmartin R, Burke B, Reder R, Goldenheim P. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59: 52–61
   PubMed Web of Science ®Google Scholar
• Kaiko R F. Pharmacokinetics and pharmacodynamics of controlled-release opioids. Acta Anaesthesiol Scand 1997; 41: 166–74
   PubMed Web of Science ®Google Scholar
• Jannetto P, Wong S, Gock S, Laleli-Sahin E, Schur B, Jentzen J. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: Genotyping cytochrome P450 2D6 for oxycodone cases. J Anal Toxicol 2002; 26: 438–47
   PubMed Web of Science ®Google Scholar
• Agundez J, Ledesma M, Ladero J, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265–9
   PubMed Web of Science ®Google Scholar
• McLellan R, Oscarson M, Seidegard J, Evans D, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 187–91
   PubMedGoogle Scholar
• deLeon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 2003; 23: 420–1
   Google Scholar
• Oxycodone. Mosby. 2002, http://www.mdconsult.com
   Google Scholar
• Tallgren M, Olkkola K T, Seppala T, Hockerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997; 61: 655–61
   PubMed Web of Science ®Google Scholar
• Kirvela M, Lindgren L, Seppala T, Olkkola K. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8: 13–8
   PubMed Web of Science ®Google Scholar
• Product Information: Roxicodone TM oxycodone. Roxane Laboratories, Inc., Columbus, OH 2000
   Google Scholar
• Poyhia R, Olkkola K, Seppala T, Kalso E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 1991; 32: 516–8
   PubMed Web of Science ®Google Scholar
• Leow K, Cramond T, Smith M. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995; 80: 296–302
   PubMed Web of Science ®Google Scholar
• Weinberg D, Inturrisi C, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44: 335–42
   PubMed Web of Science ®Google Scholar
• Takala A, Kaasalainen V, Seppala T, Kalso E, Olkkola K. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 1997; 41: 309–12
   PubMed Web of Science ®Google Scholar
• Brunk F, Delle M. Morphine metabolism in man. Clin Pharmacol Ther 1974; 16: 51–7
   PubMed Web of Science ®Google Scholar
• Sawe J, Dahlstrom B, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981; 30: 629–35
   PubMed Web of Science ®Google Scholar
• Sawe J, Svensson J O, Rane A. Morphine metabolism in cancer patients on increasing oral dosesno evidence for autoinduction or dose-dependence. Br J Clin Pharmacol 1983; 16: 85–93
   PubMed Web of Science ®Google Scholar
• Osborne R, Joel S, Trew D, Sleven M. Morphine and metabolite behavior after different routes of administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12–9
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73: 37–45
   PubMed Web of Science ®Google Scholar
• Curtis G, Johnson G, Clark P, et al. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 1999; 55: 425–9
   PubMed Web of Science ®Google Scholar
• Olkkola K, Hamunen K, Seppala T, Maunuksela E. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1994; 38: 71–6
   PubMed Web of Science ®Google Scholar
• Taketomo C K, Hodding J H, Kraus D M. Pediatric Dosage Handbook, 6th ed. Lexi-Comp, Inc, Hudson, OH 1999–2000
   Google Scholar